Lead Product(s): Aprocitentan
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Deal Size: $341.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 20, 2020
The net proceeds from this offering will help Idorsia to prepare to launch its first commercial product and continue to fund the development of its pipeline candidates including aprocitentan, clazosentan and lucerastat, as well as its early-stage and preclinical pipeline.